Core Viewpoint - Tectonic Therapeutic, Inc. has appointed François Nader, M.D., MBA, as an independent director and Chair of the Board, effective April 1, 2026, marking a significant leadership transition within the company [1][2][3]. Group 1: Leadership Changes - François Nader will assume the role of Chair of the Board, succeeding Terry McGuire, who will remain on the Board until the 2026 Annual Meeting of Stockholders, anticipated in June 2026 [2]. - Terry McGuire expressed support for Dr. Nader's appointment, highlighting the importance of this transition as Tectonic evolves to its next growth stage [3]. Group 2: Dr. Nader's Background - Dr. Nader brings over 30 years of experience in the biotechnology and pharmaceutical industry, currently serving as an Independent Director of Moderna, Inc. [2]. - His previous roles include Chairman and Executive Chairman of various biotechnology companies, leading to significant strategic transactions, including acquisitions by major pharmaceutical firms [2][3]. Group 3: Company Overview - Tectonic Therapeutic focuses on the discovery and development of therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs) [1][4]. - The company utilizes its proprietary technology platform, GEODe™, to develop biologic medicines aimed at addressing significant unmet medical needs [4].
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board